nodes	percent_of_prediction	percent_of_DWPC	metapath
Rilpivirine—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0962	0.116	CbGbCtD
Rilpivirine—CYP1A2—Clobetasol propionate—psoriasis	0.0608	0.0736	CbGbCtD
Rilpivirine—SLCO1B1—Mycophenolate mofetil—psoriasis	0.056	0.0678	CbGbCtD
Rilpivirine—ABCG2—Mycophenolate mofetil—psoriasis	0.0445	0.0539	CbGbCtD
Rilpivirine—SLCO1B1—Cyclosporine—psoriasis	0.0424	0.0514	CbGbCtD
Rilpivirine—SLCO1B3—Methotrexate—psoriasis	0.0386	0.0467	CbGbCtD
Rilpivirine—CYP2B6—Cholecalciferol—psoriasis	0.0361	0.0437	CbGbCtD
Rilpivirine—ABCG2—Hydrocortisone—psoriasis	0.0357	0.0432	CbGbCtD
Rilpivirine—ABCG2—Cyclosporine—psoriasis	0.0337	0.0408	CbGbCtD
Rilpivirine—CYP1A2—Methoxsalen—psoriasis	0.0319	0.0387	CbGbCtD
Rilpivirine—CYP2C19—Cholecalciferol—psoriasis	0.0229	0.0278	CbGbCtD
Rilpivirine—SLCO1B1—Methotrexate—psoriasis	0.0225	0.0272	CbGbCtD
Rilpivirine—ABCG2—Dexamethasone—psoriasis	0.0222	0.0269	CbGbCtD
Rilpivirine—CYP3A4—Calcitriol—psoriasis	0.0215	0.0261	CbGbCtD
Rilpivirine—ABCG2—Methotrexate—psoriasis	0.0178	0.0216	CbGbCtD
Rilpivirine—CYP3A4—Methoxsalen—psoriasis	0.0167	0.0203	CbGbCtD
Rilpivirine—ABCB1—Mycophenolate mofetil—psoriasis	0.016	0.0194	CbGbCtD
Rilpivirine—CYP2C19—Prednisone—psoriasis	0.0159	0.0192	CbGbCtD
Rilpivirine—CYP2B6—Dexamethasone—psoriasis	0.0156	0.0189	CbGbCtD
Rilpivirine—CYP2C19—Cyclosporine—psoriasis	0.0151	0.0182	CbGbCtD
Rilpivirine—ABCB1—Betamethasone—psoriasis	0.0138	0.0167	CbGbCtD
Rilpivirine—ABCB1—Prednisolone—psoriasis	0.0136	0.0164	CbGbCtD
Rilpivirine—ABCB1—Hydrocortisone—psoriasis	0.0129	0.0156	CbGbCtD
Rilpivirine—ABCB1—Prednisone—psoriasis	0.0128	0.0155	CbGbCtD
Rilpivirine—ABCB1—Cyclosporine—psoriasis	0.0122	0.0147	CbGbCtD
Rilpivirine—CYP3A4—Cholecalciferol—psoriasis	0.0111	0.0134	CbGbCtD
Rilpivirine—CYP2C19—Dexamethasone—psoriasis	0.00992	0.012	CbGbCtD
Rilpivirine—CYP3A4—Triamcinolone—psoriasis	0.00961	0.0116	CbGbCtD
Rilpivirine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00961	0.0116	CbGbCtD
Rilpivirine—CYP3A4—Betamethasone—psoriasis	0.00825	0.00999	CbGbCtD
Rilpivirine—CYP3A4—Prednisolone—psoriasis	0.00814	0.00985	CbGbCtD
Rilpivirine—ABCB1—Dexamethasone—psoriasis	0.00801	0.0097	CbGbCtD
Rilpivirine—CYP3A4—Hydrocortisone—psoriasis	0.00771	0.00934	CbGbCtD
Rilpivirine—CYP3A4—Prednisone—psoriasis	0.00768	0.00931	CbGbCtD
Rilpivirine—CYP3A4—Cyclosporine—psoriasis	0.00729	0.00882	CbGbCtD
Rilpivirine—ABCB1—Methotrexate—psoriasis	0.00643	0.00779	CbGbCtD
Rilpivirine—CYP3A4—Dexamethasone—psoriasis	0.0048	0.00581	CbGbCtD
Rilpivirine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00149	0.0692	CbGpPWpGaD
Rilpivirine—NR1I2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00121	0.0559	CbGpPWpGaD
Rilpivirine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00113	0.0523	CbGpPWpGaD
Rilpivirine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000926	0.0429	CbGpPWpGaD
Rilpivirine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.0007	0.0324	CbGpPWpGaD
Rilpivirine—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000694	0.0321	CbGpPWpGaD
Rilpivirine—NR1I2—Nuclear Receptors—VDR—psoriasis	0.000635	0.0294	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000548	0.0254	CbGpPWpGaD
Rilpivirine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000545	0.0252	CbGpPWpGaD
Rilpivirine—NR1I2—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000502	0.0232	CbGpPWpGaD
Rilpivirine—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000484	0.0224	CbGpPWpGaD
Rilpivirine—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000453	0.021	CbGpPWpGaD
Rilpivirine—NR1I2—Nuclear Receptors—PPARG—psoriasis	0.000443	0.0205	CbGpPWpGaD
Rilpivirine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000421	0.0195	CbGpPWpGaD
Rilpivirine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000385	0.0178	CbGpPWpGaD
Rilpivirine—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000381	0.0025	CcSEcCtD
Rilpivirine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000379	0.0176	CbGpPWpGaD
Rilpivirine—Inflammation—Methotrexate—psoriasis	0.000376	0.00247	CcSEcCtD
Rilpivirine—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.000376	0.00246	CcSEcCtD
Rilpivirine—Dizziness—Methoxsalen—psoriasis	0.000369	0.00242	CcSEcCtD
Rilpivirine—Depression—Cyclosporine—psoriasis	0.000368	0.00241	CcSEcCtD
Rilpivirine—Renal failure—Cyclosporine—psoriasis	0.000363	0.00238	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Acitretin—psoriasis	0.000362	0.00237	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.00036	0.00236	CcSEcCtD
Rilpivirine—Depression—Mycophenolate mofetil—psoriasis	0.000359	0.00235	CcSEcCtD
Rilpivirine—Mental disorder—Mycophenolic acid—psoriasis	0.000359	0.00235	CcSEcCtD
Rilpivirine—Asthenia—Calcitriol—psoriasis	0.000357	0.00234	CcSEcCtD
Rilpivirine—Malnutrition—Mycophenolic acid—psoriasis	0.000357	0.00234	CcSEcCtD
Rilpivirine—Renal failure—Mycophenolate mofetil—psoriasis	0.000354	0.00232	CcSEcCtD
Rilpivirine—Rash—Methoxsalen—psoriasis	0.000352	0.00231	CcSEcCtD
Rilpivirine—Dermatitis—Methoxsalen—psoriasis	0.000352	0.00231	CcSEcCtD
Rilpivirine—ABCG2—Iron uptake and transport—CP—psoriasis	0.000351	0.0162	CbGpPWpGaD
Rilpivirine—Abdominal pain—Acitretin—psoriasis	0.00035	0.00229	CcSEcCtD
Rilpivirine—Headache—Methoxsalen—psoriasis	0.00035	0.00229	CcSEcCtD
Rilpivirine—NR1I2—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00035	0.0162	CbGpPWpGaD
Rilpivirine—Hepatobiliary disease—Cyclosporine—psoriasis	0.000349	0.00229	CcSEcCtD
Rilpivirine—Infection—Hydroxyurea—psoriasis	0.000345	0.00226	CcSEcCtD
Rilpivirine—Nervous system disorder—Hydroxyurea—psoriasis	0.000341	0.00223	CcSEcCtD
Rilpivirine—Hepatobiliary disease—Mycophenolate mofetil—psoriasis	0.000341	0.00223	CcSEcCtD
Rilpivirine—Diarrhoea—Calcitriol—psoriasis	0.000341	0.00223	CcSEcCtD
Rilpivirine—Skin disorder—Hydroxyurea—psoriasis	0.000338	0.00221	CcSEcCtD
Rilpivirine—Nausea—Methoxsalen—psoriasis	0.000332	0.00217	CcSEcCtD
Rilpivirine—Urinary tract disorder—Cyclosporine—psoriasis	0.000327	0.00215	CcSEcCtD
Rilpivirine—Urethral disorder—Cyclosporine—psoriasis	0.000325	0.00213	CcSEcCtD
Rilpivirine—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000319	0.00209	CcSEcCtD
Rilpivirine—Asthenia—Acitretin—psoriasis	0.000318	0.00208	CcSEcCtD
Rilpivirine—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000317	0.00208	CcSEcCtD
Rilpivirine—Vomiting—Calcitriol—psoriasis	0.000316	0.00207	CcSEcCtD
Rilpivirine—Rash—Calcitriol—psoriasis	0.000314	0.00206	CcSEcCtD
Rilpivirine—Dermatitis—Calcitriol—psoriasis	0.000314	0.00206	CcSEcCtD
Rilpivirine—Headache—Calcitriol—psoriasis	0.000312	0.00204	CcSEcCtD
Rilpivirine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000312	0.0144	CbGpPWpGaD
Rilpivirine—Somnolence—Hydroxyurea—psoriasis	0.000309	0.00203	CcSEcCtD
Rilpivirine—Diarrhoea—Acitretin—psoriasis	0.000303	0.00199	CcSEcCtD
Rilpivirine—Anxiety—Mycophenolic acid—psoriasis	0.000303	0.00198	CcSEcCtD
Rilpivirine—Decreased appetite—Hydroxyurea—psoriasis	0.000302	0.00198	CcSEcCtD
Rilpivirine—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000302	0.00198	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000302	0.00198	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.0003	0.00197	CcSEcCtD
Rilpivirine—Fatigue—Hydroxyurea—psoriasis	0.0003	0.00196	CcSEcCtD
Rilpivirine—Dry mouth—Mycophenolic acid—psoriasis	0.000297	0.00195	CcSEcCtD
Rilpivirine—Nausea—Calcitriol—psoriasis	0.000296	0.00194	CcSEcCtD
Rilpivirine—Dizziness—Acitretin—psoriasis	0.000293	0.00192	CcSEcCtD
Rilpivirine—Dizziness—Fluocinolone Acetonide—psoriasis	0.000292	0.00191	CcSEcCtD
Rilpivirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000291	0.0135	CbGpPWpGaD
Rilpivirine—Mental disorder—Cyclosporine—psoriasis	0.00029	0.0019	CcSEcCtD
Rilpivirine—Infection—Mycophenolic acid—psoriasis	0.000289	0.0019	CcSEcCtD
Rilpivirine—Malnutrition—Cyclosporine—psoriasis	0.000289	0.00189	CcSEcCtD
Rilpivirine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000287	0.0133	CbGpPWpGaD
Rilpivirine—Nervous system disorder—Mycophenolic acid—psoriasis	0.000286	0.00187	CcSEcCtD
Rilpivirine—Mental disorder—Mycophenolate mofetil—psoriasis	0.000283	0.00186	CcSEcCtD
Rilpivirine—Skin disorder—Mycophenolic acid—psoriasis	0.000283	0.00185	CcSEcCtD
Rilpivirine—Malnutrition—Mycophenolate mofetil—psoriasis	0.000282	0.00185	CcSEcCtD
Rilpivirine—Vomiting—Acitretin—psoriasis	0.000282	0.00185	CcSEcCtD
Rilpivirine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000281	0.00184	CcSEcCtD
Rilpivirine—Alanine aminotransferase increased—Prednisone—psoriasis	0.000279	0.00183	CcSEcCtD
Rilpivirine—Rash—Acitretin—psoriasis	0.000279	0.00183	CcSEcCtD
Rilpivirine—Dermatitis—Acitretin—psoriasis	0.000279	0.00183	CcSEcCtD
Rilpivirine—Rash—Fluocinolone Acetonide—psoriasis	0.000278	0.00182	CcSEcCtD
Rilpivirine—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000278	0.00182	CcSEcCtD
Rilpivirine—Headache—Acitretin—psoriasis	0.000277	0.00182	CcSEcCtD
Rilpivirine—Headache—Fluocinolone Acetonide—psoriasis	0.000277	0.00181	CcSEcCtD
Rilpivirine—Immune system disorder—Hydrocortisone—psoriasis	0.000266	0.00174	CcSEcCtD
Rilpivirine—Insomnia—Mycophenolic acid—psoriasis	0.000263	0.00173	CcSEcCtD
Rilpivirine—Nausea—Acitretin—psoriasis	0.000263	0.00172	CcSEcCtD
Rilpivirine—Nausea—Fluocinolone Acetonide—psoriasis	0.000262	0.00172	CcSEcCtD
Rilpivirine—Somnolence—Mycophenolic acid—psoriasis	0.000259	0.0017	CcSEcCtD
Rilpivirine—Mental disorder—Hydrocortisone—psoriasis	0.000258	0.00169	CcSEcCtD
Rilpivirine—Malnutrition—Hydrocortisone—psoriasis	0.000256	0.00168	CcSEcCtD
Rilpivirine—Decreased appetite—Mycophenolic acid—psoriasis	0.000253	0.00166	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000251	0.00165	CcSEcCtD
Rilpivirine—Fatigue—Mycophenolic acid—psoriasis	0.000251	0.00165	CcSEcCtD
Rilpivirine—Asthenia—Hydroxyurea—psoriasis	0.000249	0.00163	CcSEcCtD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000249	0.0115	CbGpPWpGaD
Rilpivirine—Anxiety—Cyclosporine—psoriasis	0.000245	0.00161	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000244	0.0016	CcSEcCtD
Rilpivirine—Depression—Prednisone—psoriasis	0.000244	0.0016	CcSEcCtD
Rilpivirine—Dry mouth—Cyclosporine—psoriasis	0.00024	0.00158	CcSEcCtD
Rilpivirine—Anxiety—Mycophenolate mofetil—psoriasis	0.000239	0.00157	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000238	0.00156	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000238	0.00156	CcSEcCtD
Rilpivirine—Diarrhoea—Hydroxyurea—psoriasis	0.000238	0.00156	CcSEcCtD
Rilpivirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000236	0.0109	CbGpPWpGaD
Rilpivirine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000234	0.00154	CcSEcCtD
Rilpivirine—Infection—Cyclosporine—psoriasis	0.000234	0.00153	CcSEcCtD
Rilpivirine—Nervous system disorder—Cyclosporine—psoriasis	0.000231	0.00151	CcSEcCtD
Rilpivirine—Abdominal pain—Mycophenolic acid—psoriasis	0.00023	0.00151	CcSEcCtD
Rilpivirine—Dizziness—Hydroxyurea—psoriasis	0.00023	0.00151	CcSEcCtD
Rilpivirine—Skin disorder—Cyclosporine—psoriasis	0.000229	0.0015	CcSEcCtD
Rilpivirine—Infection—Mycophenolate mofetil—psoriasis	0.000228	0.0015	CcSEcCtD
Rilpivirine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000227	0.0105	CbGpPWpGaD
Rilpivirine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000226	0.0105	CbGpPWpGaD
Rilpivirine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000225	0.00148	CcSEcCtD
Rilpivirine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000223	0.0103	CbGpPWpGaD
Rilpivirine—Skin disorder—Mycophenolate mofetil—psoriasis	0.000223	0.00146	CcSEcCtD
Rilpivirine—NR1I2—Gene Expression—TARS—psoriasis	0.000222	0.0103	CbGpPWpGaD
Rilpivirine—Vomiting—Hydroxyurea—psoriasis	0.000221	0.00145	CcSEcCtD
Rilpivirine—Abdominal discomfort—Methotrexate—psoriasis	0.000219	0.00144	CcSEcCtD
Rilpivirine—Rash—Hydroxyurea—psoriasis	0.000219	0.00144	CcSEcCtD
Rilpivirine—Dermatitis—Hydroxyurea—psoriasis	0.000219	0.00144	CcSEcCtD
Rilpivirine—Headache—Hydroxyurea—psoriasis	0.000218	0.00143	CcSEcCtD
Rilpivirine—Anxiety—Hydrocortisone—psoriasis	0.000218	0.00143	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000217	0.00142	CcSEcCtD
Rilpivirine—Insomnia—Cyclosporine—psoriasis	0.000213	0.0014	CcSEcCtD
Rilpivirine—Somnolence—Cyclosporine—psoriasis	0.000209	0.00137	CcSEcCtD
Rilpivirine—Asthenia—Mycophenolic acid—psoriasis	0.000209	0.00137	CcSEcCtD
Rilpivirine—Infection—Hydrocortisone—psoriasis	0.000208	0.00136	CcSEcCtD
Rilpivirine—Insomnia—Mycophenolate mofetil—psoriasis	0.000208	0.00136	CcSEcCtD
Rilpivirine—Nausea—Hydroxyurea—psoriasis	0.000206	0.00135	CcSEcCtD
Rilpivirine—Nervous system disorder—Hydrocortisone—psoriasis	0.000205	0.00135	CcSEcCtD
Rilpivirine—Decreased appetite—Cyclosporine—psoriasis	0.000205	0.00134	CcSEcCtD
Rilpivirine—Somnolence—Mycophenolate mofetil—psoriasis	0.000204	0.00134	CcSEcCtD
Rilpivirine—Depression—Methotrexate—psoriasis	0.000204	0.00133	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000203	0.00133	CcSEcCtD
Rilpivirine—Skin disorder—Hydrocortisone—psoriasis	0.000203	0.00133	CcSEcCtD
Rilpivirine—Fatigue—Cyclosporine—psoriasis	0.000203	0.00133	CcSEcCtD
Rilpivirine—Dry mouth—Triamcinolone—psoriasis	0.000201	0.00132	CcSEcCtD
Rilpivirine—Renal failure—Methotrexate—psoriasis	0.000201	0.00132	CcSEcCtD
Rilpivirine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.0002	0.00131	CcSEcCtD
Rilpivirine—Diarrhoea—Mycophenolic acid—psoriasis	0.000199	0.00131	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000198	0.0013	CcSEcCtD
Rilpivirine—Immune system disorder—Prednisone—psoriasis	0.000198	0.0013	CcSEcCtD
Rilpivirine—Infection—Triamcinolone—psoriasis	0.000196	0.00128	CcSEcCtD
Rilpivirine—Insomnia—Prednisolone—psoriasis	0.000194	0.00127	CcSEcCtD
Rilpivirine—Hepatobiliary disease—Methotrexate—psoriasis	0.000193	0.00127	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000193	0.00126	CcSEcCtD
Rilpivirine—Dizziness—Mycophenolic acid—psoriasis	0.000193	0.00126	CcSEcCtD
Rilpivirine—Mental disorder—Prednisone—psoriasis	0.000192	0.00126	CcSEcCtD
Rilpivirine—Malnutrition—Prednisone—psoriasis	0.000191	0.00125	CcSEcCtD
Rilpivirine—Insomnia—Hydrocortisone—psoriasis	0.000189	0.00124	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000188	0.00123	CcSEcCtD
Rilpivirine—Abdominal pain—Cyclosporine—psoriasis	0.000186	0.00122	CcSEcCtD
Rilpivirine—Anxiety—Betamethasone—psoriasis	0.000186	0.00122	CcSEcCtD
Rilpivirine—Anxiety—Dexamethasone—psoriasis	0.000186	0.00122	CcSEcCtD
Rilpivirine—Vomiting—Mycophenolic acid—psoriasis	0.000185	0.00121	CcSEcCtD
Rilpivirine—Rash—Mycophenolic acid—psoriasis	0.000184	0.0012	CcSEcCtD
Rilpivirine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000184	0.0085	CbGpPWpGaD
Rilpivirine—Dermatitis—Mycophenolic acid—psoriasis	0.000183	0.0012	CcSEcCtD
Rilpivirine—Headache—Mycophenolic acid—psoriasis	0.000182	0.0012	CcSEcCtD
Rilpivirine—Decreased appetite—Hydrocortisone—psoriasis	0.000182	0.00119	CcSEcCtD
Rilpivirine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000182	0.00119	CcSEcCtD
Rilpivirine—Urinary tract disorder—Methotrexate—psoriasis	0.000181	0.00119	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000181	0.00118	CcSEcCtD
Rilpivirine—Fatigue—Hydrocortisone—psoriasis	0.00018	0.00118	CcSEcCtD
Rilpivirine—Urethral disorder—Methotrexate—psoriasis	0.00018	0.00118	CcSEcCtD
Rilpivirine—Insomnia—Triamcinolone—psoriasis	0.000178	0.00117	CcSEcCtD
Rilpivirine—Infection—Betamethasone—psoriasis	0.000178	0.00116	CcSEcCtD
Rilpivirine—Infection—Dexamethasone—psoriasis	0.000178	0.00116	CcSEcCtD
Rilpivirine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000177	0.00818	CbGpPWpGaD
Rilpivirine—Nervous system disorder—Betamethasone—psoriasis	0.000175	0.00115	CcSEcCtD
Rilpivirine—Nervous system disorder—Dexamethasone—psoriasis	0.000175	0.00115	CcSEcCtD
Rilpivirine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000175	0.00809	CbGpPWpGaD
Rilpivirine—Nausea—Mycophenolic acid—psoriasis	0.000173	0.00113	CcSEcCtD
Rilpivirine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000172	0.00799	CbGpPWpGaD
Rilpivirine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000171	0.00112	CcSEcCtD
Rilpivirine—Fatigue—Triamcinolone—psoriasis	0.00017	0.00111	CcSEcCtD
Rilpivirine—Asthenia—Cyclosporine—psoriasis	0.000169	0.00111	CcSEcCtD
Rilpivirine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000166	0.00767	CbGpPWpGaD
Rilpivirine—Immune system disorder—Methotrexate—psoriasis	0.000165	0.00108	CcSEcCtD
Rilpivirine—Abdominal pain—Hydrocortisone—psoriasis	0.000165	0.00108	CcSEcCtD
Rilpivirine—Asthenia—Mycophenolate mofetil—psoriasis	0.000165	0.00108	CcSEcCtD
Rilpivirine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000163	0.00756	CbGpPWpGaD
Rilpivirine—Anxiety—Prednisone—psoriasis	0.000162	0.00106	CcSEcCtD
Rilpivirine—Insomnia—Dexamethasone—psoriasis	0.000162	0.00106	CcSEcCtD
Rilpivirine—Insomnia—Betamethasone—psoriasis	0.000162	0.00106	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000161	0.00106	CcSEcCtD
Rilpivirine—Diarrhoea—Cyclosporine—psoriasis	0.000161	0.00106	CcSEcCtD
Rilpivirine—Mental disorder—Methotrexate—psoriasis	0.000161	0.00105	CcSEcCtD
Rilpivirine—Malnutrition—Methotrexate—psoriasis	0.000159	0.00105	CcSEcCtD
Rilpivirine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000157	0.00103	CcSEcCtD
Rilpivirine—Dizziness—Cyclosporine—psoriasis	0.000156	0.00102	CcSEcCtD
Rilpivirine—Decreased appetite—Dexamethasone—psoriasis	0.000155	0.00102	CcSEcCtD
Rilpivirine—Decreased appetite—Betamethasone—psoriasis	0.000155	0.00102	CcSEcCtD
Rilpivirine—Infection—Prednisone—psoriasis	0.000155	0.00101	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000154	0.00101	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000154	0.00101	CcSEcCtD
Rilpivirine—Fatigue—Betamethasone—psoriasis	0.000154	0.00101	CcSEcCtD
Rilpivirine—Fatigue—Dexamethasone—psoriasis	0.000154	0.00101	CcSEcCtD
Rilpivirine—Nervous system disorder—Prednisone—psoriasis	0.000153	0.001	CcSEcCtD
Rilpivirine—Dizziness—Mycophenolate mofetil—psoriasis	0.000152	0.000996	CcSEcCtD
Rilpivirine—Skin disorder—Prednisone—psoriasis	0.000151	0.000992	CcSEcCtD
Rilpivirine—Asthenia—Hydrocortisone—psoriasis	0.00015	0.000985	CcSEcCtD
Rilpivirine—Vomiting—Cyclosporine—psoriasis	0.00015	0.000982	CcSEcCtD
Rilpivirine—Rash—Cyclosporine—psoriasis	0.000149	0.000974	CcSEcCtD
Rilpivirine—Dermatitis—Cyclosporine—psoriasis	0.000148	0.000973	CcSEcCtD
Rilpivirine—Headache—Cyclosporine—psoriasis	0.000148	0.000967	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000146	0.000959	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Betamethasone—psoriasis	0.000146	0.000959	CcSEcCtD
Rilpivirine—Vomiting—Mycophenolate mofetil—psoriasis	0.000146	0.000958	CcSEcCtD
Rilpivirine—NR1I2—Generic Transcription Pathway—CARM1—psoriasis	0.000145	0.00672	CbGpPWpGaD
Rilpivirine—Rash—Mycophenolate mofetil—psoriasis	0.000145	0.00095	CcSEcCtD
Rilpivirine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000145	0.000949	CcSEcCtD
Rilpivirine—Headache—Mycophenolate mofetil—psoriasis	0.000144	0.000944	CcSEcCtD
Rilpivirine—Diarrhoea—Hydrocortisone—psoriasis	0.000143	0.000939	CcSEcCtD
Rilpivirine—Dizziness—Prednisolone—psoriasis	0.000142	0.000929	CcSEcCtD
Rilpivirine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000142	0.00656	CbGpPWpGaD
Rilpivirine—Asthenia—Triamcinolone—psoriasis	0.000141	0.000927	CcSEcCtD
Rilpivirine—Abdominal pain—Betamethasone—psoriasis	0.000141	0.000927	CcSEcCtD
Rilpivirine—Abdominal pain—Dexamethasone—psoriasis	0.000141	0.000927	CcSEcCtD
Rilpivirine—Insomnia—Prednisone—psoriasis	0.000141	0.000923	CcSEcCtD
Rilpivirine—Nausea—Cyclosporine—psoriasis	0.00014	0.000917	CcSEcCtD
Rilpivirine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00014	0.00647	CbGpPWpGaD
Rilpivirine—Dizziness—Hydrocortisone—psoriasis	0.000138	0.000907	CcSEcCtD
Rilpivirine—Nausea—Mycophenolate mofetil—psoriasis	0.000136	0.000895	CcSEcCtD
Rilpivirine—Decreased appetite—Prednisone—psoriasis	0.000135	0.000888	CcSEcCtD
Rilpivirine—Rash—Prednisolone—psoriasis	0.000135	0.000886	CcSEcCtD
Rilpivirine—Dermatitis—Prednisolone—psoriasis	0.000135	0.000885	CcSEcCtD
Rilpivirine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000135	0.000884	CcSEcCtD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000135	0.00623	CbGpPWpGaD
Rilpivirine—Fatigue—Prednisone—psoriasis	0.000134	0.00088	CcSEcCtD
Rilpivirine—Headache—Prednisolone—psoriasis	0.000134	0.00088	CcSEcCtD
Rilpivirine—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	0.000134	0.00618	CbGpPWpGaD
Rilpivirine—Vomiting—Hydrocortisone—psoriasis	0.000133	0.000872	CcSEcCtD
Rilpivirine—Rash—Hydrocortisone—psoriasis	0.000132	0.000865	CcSEcCtD
Rilpivirine—Dermatitis—Hydrocortisone—psoriasis	0.000132	0.000864	CcSEcCtD
Rilpivirine—Headache—Hydrocortisone—psoriasis	0.000131	0.00086	CcSEcCtD
Rilpivirine—Dizziness—Triamcinolone—psoriasis	0.00013	0.000854	CcSEcCtD
Rilpivirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00013	0.00603	CbGpPWpGaD
Rilpivirine—Infection—Methotrexate—psoriasis	0.000129	0.000848	CcSEcCtD
Rilpivirine—Asthenia—Betamethasone—psoriasis	0.000128	0.000841	CcSEcCtD
Rilpivirine—Asthenia—Dexamethasone—psoriasis	0.000128	0.000841	CcSEcCtD
Rilpivirine—Nervous system disorder—Methotrexate—psoriasis	0.000128	0.000837	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Prednisone—psoriasis	0.000127	0.000835	CcSEcCtD
Rilpivirine—Nausea—Prednisolone—psoriasis	0.000127	0.000835	CcSEcCtD
Rilpivirine—Skin disorder—Methotrexate—psoriasis	0.000126	0.000829	CcSEcCtD
Rilpivirine—Vomiting—Triamcinolone—psoriasis	0.000125	0.000822	CcSEcCtD
Rilpivirine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000125	0.00579	CbGpPWpGaD
Rilpivirine—Nausea—Hydrocortisone—psoriasis	0.000124	0.000815	CcSEcCtD
Rilpivirine—Rash—Triamcinolone—psoriasis	0.000124	0.000815	CcSEcCtD
Rilpivirine—Dermatitis—Triamcinolone—psoriasis	0.000124	0.000814	CcSEcCtD
Rilpivirine—Headache—Triamcinolone—psoriasis	0.000123	0.000809	CcSEcCtD
Rilpivirine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000123	0.00571	CbGpPWpGaD
Rilpivirine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000123	0.0057	CbGpPWpGaD
Rilpivirine—Abdominal pain—Prednisone—psoriasis	0.000123	0.000807	CcSEcCtD
Rilpivirine—Diarrhoea—Dexamethasone—psoriasis	0.000122	0.000802	CcSEcCtD
Rilpivirine—Diarrhoea—Betamethasone—psoriasis	0.000122	0.000802	CcSEcCtD
Rilpivirine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000121	0.00562	CbGpPWpGaD
Rilpivirine—Dizziness—Betamethasone—psoriasis	0.000118	0.000775	CcSEcCtD
Rilpivirine—Dizziness—Dexamethasone—psoriasis	0.000118	0.000775	CcSEcCtD
Rilpivirine—Insomnia—Methotrexate—psoriasis	0.000118	0.000772	CcSEcCtD
Rilpivirine—Nausea—Triamcinolone—psoriasis	0.000117	0.000767	CcSEcCtD
Rilpivirine—Somnolence—Methotrexate—psoriasis	0.000116	0.000759	CcSEcCtD
Rilpivirine—Vomiting—Dexamethasone—psoriasis	0.000114	0.000745	CcSEcCtD
Rilpivirine—Vomiting—Betamethasone—psoriasis	0.000114	0.000745	CcSEcCtD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000113	0.00525	CbGpPWpGaD
Rilpivirine—Decreased appetite—Methotrexate—psoriasis	0.000113	0.000742	CcSEcCtD
Rilpivirine—Rash—Betamethasone—psoriasis	0.000113	0.000739	CcSEcCtD
Rilpivirine—Rash—Dexamethasone—psoriasis	0.000113	0.000739	CcSEcCtD
Rilpivirine—Dermatitis—Dexamethasone—psoriasis	0.000113	0.000739	CcSEcCtD
Rilpivirine—Dermatitis—Betamethasone—psoriasis	0.000113	0.000739	CcSEcCtD
Rilpivirine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000112	0.000737	CcSEcCtD
Rilpivirine—Fatigue—Methotrexate—psoriasis	0.000112	0.000736	CcSEcCtD
Rilpivirine—Headache—Dexamethasone—psoriasis	0.000112	0.000734	CcSEcCtD
Rilpivirine—Headache—Betamethasone—psoriasis	0.000112	0.000734	CcSEcCtD
Rilpivirine—Asthenia—Prednisone—psoriasis	0.000112	0.000733	CcSEcCtD
Rilpivirine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000111	0.00514	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000109	0.00503	CbGpPWpGaD
Rilpivirine—Diarrhoea—Prednisone—psoriasis	0.000107	0.000699	CcSEcCtD
Rilpivirine—Gastrointestinal pain—Methotrexate—psoriasis	0.000106	0.000698	CcSEcCtD
Rilpivirine—Nausea—Dexamethasone—psoriasis	0.000106	0.000696	CcSEcCtD
Rilpivirine—Nausea—Betamethasone—psoriasis	0.000106	0.000696	CcSEcCtD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000106	0.0049	CbGpPWpGaD
Rilpivirine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000104	0.00482	CbGpPWpGaD
Rilpivirine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000104	0.00482	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000104	0.00481	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000103	0.00478	CbGpPWpGaD
Rilpivirine—Dizziness—Prednisone—psoriasis	0.000103	0.000675	CcSEcCtD
Rilpivirine—Abdominal pain—Methotrexate—psoriasis	0.000103	0.000675	CcSEcCtD
Rilpivirine—Vomiting—Prednisone—psoriasis	9.9e-05	0.000649	CcSEcCtD
Rilpivirine—Rash—Prednisone—psoriasis	9.82e-05	0.000644	CcSEcCtD
Rilpivirine—Dermatitis—Prednisone—psoriasis	9.81e-05	0.000643	CcSEcCtD
Rilpivirine—Headache—Prednisone—psoriasis	9.76e-05	0.00064	CcSEcCtD
Rilpivirine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	9.75e-05	0.00451	CbGpPWpGaD
Rilpivirine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	9.62e-05	0.00445	CbGpPWpGaD
Rilpivirine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	9.6e-05	0.00444	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—IL17A—psoriasis	9.5e-05	0.0044	CbGpPWpGaD
Rilpivirine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	9.45e-05	0.00438	CbGpPWpGaD
Rilpivirine—Asthenia—Methotrexate—psoriasis	9.34e-05	0.000612	CcSEcCtD
Rilpivirine—Nausea—Prednisone—psoriasis	9.25e-05	0.000606	CcSEcCtD
Rilpivirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.08e-05	0.00421	CbGpPWpGaD
Rilpivirine—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	8.97e-05	0.00416	CbGpPWpGaD
Rilpivirine—Diarrhoea—Methotrexate—psoriasis	8.91e-05	0.000584	CcSEcCtD
Rilpivirine—ABCB1—Allograft Rejection—IL12B—psoriasis	8.83e-05	0.00409	CbGpPWpGaD
Rilpivirine—NR1I2—Generic Transcription Pathway—VDR—psoriasis	8.67e-05	0.00401	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—HLA-E—psoriasis	8.62e-05	0.00399	CbGpPWpGaD
Rilpivirine—Dizziness—Methotrexate—psoriasis	8.61e-05	0.000564	CcSEcCtD
Rilpivirine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	8.41e-05	0.0039	CbGpPWpGaD
Rilpivirine—Vomiting—Methotrexate—psoriasis	8.28e-05	0.000543	CcSEcCtD
Rilpivirine—Rash—Methotrexate—psoriasis	8.21e-05	0.000538	CcSEcCtD
Rilpivirine—Dermatitis—Methotrexate—psoriasis	8.2e-05	0.000537	CcSEcCtD
Rilpivirine—Headache—Methotrexate—psoriasis	8.15e-05	0.000535	CcSEcCtD
Rilpivirine—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	8.06e-05	0.00373	CbGpPWpGaD
Rilpivirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.03e-05	0.00372	CbGpPWpGaD
Rilpivirine—Nausea—Methotrexate—psoriasis	7.73e-05	0.000507	CcSEcCtD
Rilpivirine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.52e-05	0.00348	CbGpPWpGaD
Rilpivirine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.42e-05	0.00344	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—NDUFA5—psoriasis	7.3e-05	0.00338	CbGpPWpGaD
Rilpivirine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.25e-05	0.00336	CbGpPWpGaD
Rilpivirine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.21e-05	0.00334	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.13e-05	0.0033	CbGpPWpGaD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	7.01e-05	0.00325	CbGpPWpGaD
Rilpivirine—NR1I2—Gene Expression—CARM1—psoriasis	6.99e-05	0.00324	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.81e-05	0.00315	CbGpPWpGaD
Rilpivirine—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	6.79e-05	0.00314	CbGpPWpGaD
Rilpivirine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.49e-05	0.00301	CbGpPWpGaD
Rilpivirine—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	6.47e-05	0.003	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—IL10—psoriasis	6.46e-05	0.00299	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—IL4—psoriasis	6.28e-05	0.00291	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—CYP2S1—psoriasis	6.21e-05	0.00288	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.14e-05	0.00284	CbGpPWpGaD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.13e-05	0.00284	CbGpPWpGaD
Rilpivirine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	6.12e-05	0.00284	CbGpPWpGaD
Rilpivirine—NR1I2—Generic Transcription Pathway—PPARG—psoriasis	6.04e-05	0.0028	CbGpPWpGaD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.72e-05	0.00265	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.69e-05	0.00263	CbGpPWpGaD
Rilpivirine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.62e-05	0.0026	CbGpPWpGaD
Rilpivirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.6e-05	0.00259	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.2e-05	0.00241	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—NDUFA5—psoriasis	4.91e-05	0.00227	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.67e-05	0.00216	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.58e-05	0.00212	CbGpPWpGaD
Rilpivirine—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	4.56e-05	0.00211	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—NDUFA5—psoriasis	4.54e-05	0.0021	CbGpPWpGaD
Rilpivirine—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	4.35e-05	0.00201	CbGpPWpGaD
Rilpivirine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	4.22e-05	0.00196	CbGpPWpGaD
Rilpivirine—NR1I2—Gene Expression—VDR—psoriasis	4.17e-05	0.00193	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—CYP2S1—psoriasis	4.17e-05	0.00193	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.04e-05	0.00187	CbGpPWpGaD
Rilpivirine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.03e-05	0.00187	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.89e-05	0.0018	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—CYP2S1—psoriasis	3.86e-05	0.00179	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—IFNG—psoriasis	3.8e-05	0.00176	CbGpPWpGaD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.79e-05	0.00175	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.53e-05	0.00163	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.53e-05	0.00163	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—NDUFA5—psoriasis	3.33e-05	0.00154	CbGpPWpGaD
Rilpivirine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.31e-05	0.00153	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.25e-05	0.00151	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—CARM1—psoriasis	3.03e-05	0.0014	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.02e-05	0.0014	CbGpPWpGaD
Rilpivirine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.02e-05	0.0014	CbGpPWpGaD
Rilpivirine—NR1I2—Gene Expression—PPARG—psoriasis	2.91e-05	0.00135	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.91e-05	0.00135	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.87e-05	0.00133	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.83e-05	0.00131	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.83e-05	0.00131	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.52e-05	0.00117	CbGpPWpGaD
Rilpivirine—ABCB1—Allograft Rejection—TNF—psoriasis	2.46e-05	0.00114	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—NDUFA5—psoriasis	2.46e-05	0.00114	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.44e-05	0.00113	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.35e-05	0.00109	CbGpPWpGaD
Rilpivirine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.28e-05	0.00106	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.19e-05	0.00101	CbGpPWpGaD
Rilpivirine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.18e-05	0.00101	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.14e-05	0.000991	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—CYP2S1—psoriasis	2.09e-05	0.000967	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—CARM1—psoriasis	2.04e-05	0.000943	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.96e-05	0.000908	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.9e-05	0.000882	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—CARM1—psoriasis	1.89e-05	0.000874	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—CAT—psoriasis	1.87e-05	0.000864	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.83e-05	0.000847	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.67e-05	0.000772	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.62e-05	0.00075	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.56e-05	0.000722	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.51e-05	0.000701	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—APOE—psoriasis	1.45e-05	0.000671	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.41e-05	0.000655	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—CARM1—psoriasis	1.38e-05	0.00064	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.29e-05	0.000596	CbGpPWpGaD
Rilpivirine—SLCO1B3—Metabolism—PPARG—psoriasis	1.26e-05	0.000585	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—CAT—psoriasis	1.25e-05	0.00058	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.21e-05	0.000561	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—CAT—psoriasis	1.16e-05	0.000537	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.12e-05	0.000519	CbGpPWpGaD
Rilpivirine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.07e-05	0.000495	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—CARM1—psoriasis	1.05e-05	0.000484	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—CARM1—psoriasis	1.02e-05	0.000472	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.77e-06	0.000452	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—APOE—psoriasis	9.74e-06	0.000451	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—APOE—psoriasis	9.02e-06	0.000418	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.74e-06	0.000405	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—CAT—psoriasis	8.51e-06	0.000394	CbGpPWpGaD
Rilpivirine—SLCO1B1—Metabolism—PPARG—psoriasis	8.48e-06	0.000393	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—CARM1—psoriasis	8.14e-06	0.000377	CbGpPWpGaD
Rilpivirine—ABCG2—Metabolism—PPARG—psoriasis	7.85e-06	0.000364	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.61e-06	0.000352	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—APOE—psoriasis	6.61e-06	0.000306	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—CAT—psoriasis	6.43e-06	0.000298	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—CARM1—psoriasis	6.28e-06	0.000291	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—CAT—psoriasis	6.27e-06	0.000291	CbGpPWpGaD
Rilpivirine—CYP2B6—Metabolism—PPARG—psoriasis	5.76e-06	0.000267	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—CAT—psoriasis	5.01e-06	0.000232	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—APOE—psoriasis	4.99e-06	0.000231	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—APOE—psoriasis	4.87e-06	0.000226	CbGpPWpGaD
Rilpivirine—CYP2C19—Metabolism—PPARG—psoriasis	4.35e-06	0.000201	CbGpPWpGaD
Rilpivirine—ABCB1—Metabolism—PPARG—psoriasis	4.25e-06	0.000197	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—APOE—psoriasis	3.89e-06	0.00018	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—CAT—psoriasis	3.87e-06	0.000179	CbGpPWpGaD
Rilpivirine—CYP1A2—Metabolism—PPARG—psoriasis	3.39e-06	0.000157	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—APOE—psoriasis	3e-06	0.000139	CbGpPWpGaD
Rilpivirine—CYP3A4—Metabolism—PPARG—psoriasis	2.62e-06	0.000121	CbGpPWpGaD
